JP2014513722A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014513722A5 JP2014513722A5 JP2014511390A JP2014511390A JP2014513722A5 JP 2014513722 A5 JP2014513722 A5 JP 2014513722A5 JP 2014511390 A JP2014511390 A JP 2014511390A JP 2014511390 A JP2014511390 A JP 2014511390A JP 2014513722 A5 JP2014513722 A5 JP 2014513722A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- therapeutic agent
- patient
- increasing
- need
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 11
- 238000000034 method Methods 0.000 claims 11
- 229940124597 therapeutic agent Drugs 0.000 claims 10
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 229960000485 methotrexate Drugs 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 208000032467 Aplastic anaemia Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 101000718525 Homo sapiens Alpha-galactosidase A Proteins 0.000 claims 1
- 101001018026 Homo sapiens Lysosomal alpha-glucosidase Proteins 0.000 claims 1
- 230000005867 T cell response Effects 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 230000005875 antibody response Effects 0.000 claims 1
- 230000005784 autoimmunity Effects 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000000779 depleting effect Effects 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 102000045921 human GAA Human genes 0.000 claims 1
- 102000043404 human GLA Human genes 0.000 claims 1
- 230000006058 immune tolerance Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 210000002707 regulatory b cell Anatomy 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161486697P | 2011-05-16 | 2011-05-16 | |
| US61/486,697 | 2011-05-16 | ||
| PCT/US2012/036405 WO2012158362A1 (en) | 2011-05-16 | 2012-05-03 | Induction of immune tolerance by using methotrexate |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017040046A Division JP6381707B2 (ja) | 2011-05-16 | 2017-03-03 | メトトレキサートを用いる免疫寛容の誘導 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014513722A JP2014513722A (ja) | 2014-06-05 |
| JP2014513722A5 true JP2014513722A5 (OSRAM) | 2015-06-25 |
| JP6174572B2 JP6174572B2 (ja) | 2017-08-02 |
Family
ID=47177257
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014511390A Active JP6174572B2 (ja) | 2011-05-16 | 2012-05-03 | メトトレキサートを用いる免疫寛容の誘導 |
| JP2017040046A Active JP6381707B2 (ja) | 2011-05-16 | 2017-03-03 | メトトレキサートを用いる免疫寛容の誘導 |
| JP2018145564A Active JP6694020B2 (ja) | 2011-05-16 | 2018-08-02 | メトトレキサートを用いる免疫寛容の誘導 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017040046A Active JP6381707B2 (ja) | 2011-05-16 | 2017-03-03 | メトトレキサートを用いる免疫寛容の誘導 |
| JP2018145564A Active JP6694020B2 (ja) | 2011-05-16 | 2018-08-02 | メトトレキサートを用いる免疫寛容の誘導 |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US20140135337A1 (OSRAM) |
| EP (2) | EP2709627B1 (OSRAM) |
| JP (3) | JP6174572B2 (OSRAM) |
| KR (3) | KR20140040744A (OSRAM) |
| CN (4) | CN113209288A (OSRAM) |
| AU (1) | AU2012256281B2 (OSRAM) |
| BR (1) | BR112013029501A2 (OSRAM) |
| CA (1) | CA2835819A1 (OSRAM) |
| CL (1) | CL2013003298A1 (OSRAM) |
| CO (1) | CO6841993A2 (OSRAM) |
| DO (1) | DOP2013000268A (OSRAM) |
| EC (1) | ECSP13013081A (OSRAM) |
| ES (1) | ES2836823T3 (OSRAM) |
| GT (1) | GT201300278A (OSRAM) |
| IL (2) | IL229245B (OSRAM) |
| MA (1) | MA35165B1 (OSRAM) |
| MX (1) | MX2013013445A (OSRAM) |
| MY (1) | MY173304A (OSRAM) |
| NI (1) | NI201300121A (OSRAM) |
| PE (1) | PE20140469A1 (OSRAM) |
| PH (1) | PH12013502256A1 (OSRAM) |
| PT (1) | PT2709627T (OSRAM) |
| RU (1) | RU2674036C2 (OSRAM) |
| SG (1) | SG194802A1 (OSRAM) |
| TN (1) | TN2013000472A1 (OSRAM) |
| UA (1) | UA117556C2 (OSRAM) |
| WO (1) | WO2012158362A1 (OSRAM) |
| ZA (1) | ZA201308315B (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8809282B2 (en) * | 2010-05-06 | 2014-08-19 | Duke University | Method of reducing titers of antibodies specific for a therapeutic agent |
| MX373641B (es) | 2011-04-29 | 2020-05-04 | Selecta Biosciences Inc | Nanoportadores sintéticos tolerogénicos para la terapia contra alergias. |
| EP2709627B1 (en) | 2011-05-16 | 2020-09-23 | Genzyme Corporation | Induction of immune tolerance by using methotrexate |
| CN105283175A (zh) * | 2013-05-03 | 2016-01-27 | 西莱克塔生物科技公司 | 用于降低的或增强的药效学作用的致耐受性合成纳米载体和治疗性大分子 |
| EA201592273A1 (ru) * | 2013-06-04 | 2016-09-30 | Селекта Байосайенсиз, Инк. | Повторное введение неиммуносупрессивных антигенспецифических иммунотерапевтических средств |
| KR20170045344A (ko) | 2014-09-07 | 2017-04-26 | 셀렉타 바이오사이언시즈, 인크. | 항-바이러스 전달 벡터 면역 반응을 약화시키기 위한 방법 및 조성물 |
| EP3283519A1 (en) | 2015-04-15 | 2018-02-21 | Regeneron Pharmaceuticals, Inc. | Methods of increasing strength and functionality with gdf8 inhibitors |
| JP2016213236A (ja) * | 2015-04-30 | 2016-12-15 | 日東電工株式会社 | 半導体装置用フィルム、及び、半導体装置の製造方法 |
| JP7523909B2 (ja) | 2017-03-11 | 2024-07-29 | セレクタ バイオサイエンシーズ インコーポレーテッド | 抗炎症剤および免疫抑制剤を含む合成ナノキャリアによる組み合わせ処置に関連する方法および組成物 |
| WO2018209300A1 (en) * | 2017-05-12 | 2018-11-15 | Duke University | Methods for the use of low-dose immune modulators transiently for treating patients undergoing protein replacement therapy |
| TWI821227B (zh) * | 2017-12-22 | 2023-11-11 | 美商健臻公司 | 胺甲喋呤誘發的免疫耐受性之生物標記 |
| IL295415A (en) | 2020-02-08 | 2022-10-01 | Genzyme Corp | Compositions and methods for treating pompe disease |
| TW202342057A (zh) * | 2022-02-07 | 2023-11-01 | 美商健生生物科技公司 | 用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4080325A (en) | 1976-11-17 | 1978-03-21 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Synthesis of methotrexate |
| US4558690A (en) | 1982-01-26 | 1985-12-17 | University Of Scranton | Method of administration of chemotherapy to tumors |
| US5108987A (en) | 1982-02-25 | 1992-04-28 | Faulk Ward P | Conjugates of proteins with anti-tumor agents |
| US5028697A (en) | 1988-08-08 | 1991-07-02 | Eli Lilly And Company | Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers |
| DE4000154A1 (de) | 1990-01-04 | 1991-07-11 | Symbiotec Gmbh | Chemotherapeutisches mittel, insbesondere zur behandlung von krebserkrankungen |
| US6015557A (en) | 1999-02-24 | 2000-01-18 | Tobinick; Edward L. | Tumor necrosis factor antagonists for the treatment of neurological disorders |
| US7485314B2 (en) * | 2002-05-06 | 2009-02-03 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Induction of antigen specific immunologic tolerance |
| WO2005085294A1 (ja) | 2004-03-05 | 2005-09-15 | Denki Kagaku Kogyo Kabushiki Kaisha | ヒアルロン酸−メトトレキサート結合体 |
| US7884196B2 (en) | 2004-10-06 | 2011-02-08 | Oliver Lawless | Vaccine composition comprising methylated DNA and immunomodulatory motifs |
| EP2918269A1 (en) * | 2006-03-02 | 2015-09-16 | Alexion Pharmaceuticals, Inc. | Prolongation of survival of an allograft by inhibiting complement activity |
| WO2008094937A2 (en) | 2007-01-29 | 2008-08-07 | Joslin Diabetes Center, Inc. | Methods of modulating angiogenesis |
| US20090155207A1 (en) * | 2007-11-29 | 2009-06-18 | Hariri Robert J | Use of Immunomodulatory Compounds for the Treatment of Transverse Myelitis, Multiple Sclerosis, and Other Disorders |
| US7914785B2 (en) * | 2008-01-02 | 2011-03-29 | Bergen Teknologieverforing As | B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
| EP2077281A1 (en) * | 2008-01-02 | 2009-07-08 | Bergen Teknologioverforing AS | Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
| CA2740077A1 (en) | 2008-10-08 | 2010-04-15 | Cambridge Enterprise Limited | Methods and compositions for diagnosis and treatment |
| MX2011004870A (es) | 2008-11-07 | 2011-09-06 | 4Sc Ag | Composicion de combinacion que comprende un inhibidor de dhodh y metotrexato para tratar enfermedades autoinmunes. |
| EP2709627B1 (en) | 2011-05-16 | 2020-09-23 | Genzyme Corporation | Induction of immune tolerance by using methotrexate |
-
2012
- 2012-05-03 EP EP12785624.3A patent/EP2709627B1/en active Active
- 2012-05-03 EP EP20197579.4A patent/EP3824890A1/en active Pending
- 2012-05-03 US US14/116,486 patent/US20140135337A1/en not_active Abandoned
- 2012-05-03 AU AU2012256281A patent/AU2012256281B2/en active Active
- 2012-05-03 CN CN202011422509.7A patent/CN113209288A/zh active Pending
- 2012-05-03 CN CN201910138372.3A patent/CN110124039A/zh active Pending
- 2012-05-03 SG SG2013082003A patent/SG194802A1/en unknown
- 2012-05-03 KR KR1020137032882A patent/KR20140040744A/ko not_active Ceased
- 2012-05-03 MX MX2013013445A patent/MX2013013445A/es unknown
- 2012-05-03 CN CN201280035299.3A patent/CN103648501A/zh active Pending
- 2012-05-03 KR KR1020197033979A patent/KR102163285B1/ko active Active
- 2012-05-03 PT PT127856243T patent/PT2709627T/pt unknown
- 2012-05-03 ES ES12785624T patent/ES2836823T3/es active Active
- 2012-05-03 BR BR112013029501A patent/BR112013029501A2/pt not_active Application Discontinuation
- 2012-05-03 CA CA2835819A patent/CA2835819A1/en not_active Abandoned
- 2012-05-03 RU RU2013155618A patent/RU2674036C2/ru active
- 2012-05-03 MY MYPI2013003998A patent/MY173304A/en unknown
- 2012-05-03 KR KR1020207027913A patent/KR102316283B1/ko active Active
- 2012-05-03 PH PH1/2013/502256A patent/PH12013502256A1/en unknown
- 2012-05-03 JP JP2014511390A patent/JP6174572B2/ja active Active
- 2012-05-03 CN CN201811398468.5A patent/CN109620830A/zh active Pending
- 2012-05-03 UA UAA201314626A patent/UA117556C2/uk unknown
- 2012-05-03 WO PCT/US2012/036405 patent/WO2012158362A1/en not_active Ceased
- 2012-05-03 PE PE2013002499A patent/PE20140469A1/es not_active Application Discontinuation
-
2013
- 2013-11-04 IL IL229245A patent/IL229245B/en active IP Right Grant
- 2013-11-06 ZA ZA2013/08315A patent/ZA201308315B/en unknown
- 2013-11-13 TN TNP2013000472A patent/TN2013000472A1/fr unknown
- 2013-11-14 GT GT201300278A patent/GT201300278A/es unknown
- 2013-11-14 NI NI201300121A patent/NI201300121A/es unknown
- 2013-11-15 CL CL2013003298A patent/CL2013003298A1/es unknown
- 2013-11-15 DO DO2013000268A patent/DOP2013000268A/es unknown
- 2013-12-04 MA MA36522A patent/MA35165B1/fr unknown
- 2013-12-05 CO CO13286019A patent/CO6841993A2/es not_active Application Discontinuation
- 2013-12-13 EC ECSP13013081 patent/ECSP13013081A/es unknown
-
2017
- 2017-03-03 JP JP2017040046A patent/JP6381707B2/ja active Active
-
2018
- 2018-08-02 JP JP2018145564A patent/JP6694020B2/ja active Active
-
2020
- 2020-03-24 US US16/828,407 patent/US11672802B2/en active Active
- 2020-08-23 IL IL276879A patent/IL276879B/en unknown
-
2023
- 2023-04-28 US US18/141,128 patent/US20230372347A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014513722A5 (OSRAM) | ||
| RU2013155618A (ru) | Индукция иммунологической толерантности, используя метотрексат | |
| EA201891154A1 (ru) | Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей | |
| JP2011225596A5 (OSRAM) | ||
| RU2018110647A (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
| EA201490004A1 (ru) | Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей | |
| JP2012041342A5 (OSRAM) | ||
| JP2015524444A5 (OSRAM) | ||
| WO2013101897A3 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| RU2015120216A (ru) | Ингибиторы тирозинкиназы брутона | |
| JP2015524472A5 (OSRAM) | ||
| MY157564A (en) | Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract | |
| HK1202776A1 (en) | Use of laquinimod for treating crohn's disease patients who failed first-line anti-tnf therapy | |
| JP2013537539A5 (OSRAM) | ||
| JP2013541583A5 (OSRAM) | ||
| RU2012124268A (ru) | Бензимидазольные соединения и их применения | |
| RU2014150942A (ru) | Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона | |
| WO2009040072A3 (en) | Use of angiotensin i as a therapeutic agent in the treatment of eg aids or tuberculosis | |
| JP2013510169A5 (OSRAM) | ||
| JP2017501140A5 (OSRAM) | ||
| JP2014532722A5 (OSRAM) | ||
| FR2996838B1 (fr) | Procede de preparation d'un oxyde mixte de titane et de niobium par traitement solvothermal ; electrode et accumulateur au lithium comprenant ledit oxyde mixte | |
| HRP20161147T1 (hr) | Farmaceutski sastav i postupak njegove proizvodnje | |
| RU2014112324A (ru) | Применение органического соединения для лечения синдрома нунан |